🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

131 results for “New” Clear

  1. IV Remodulin

    United Therapeutics Europe Ltd

    Persistent Pulmonary Hypertension of the Newborn

    phase 2 small molecule terminated

    1 trial

  2. Investigational new drug company code: BGS649

    Mereo BioPharma Group plc

    Obese Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  3. Itacitinib, placebo of itacitinib 100mg

    Pari Pharma GmbH

    Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening

    phase 2 small molecule active

    1 trial

  4. Ixazomib

    Takeda

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  5. JNJ-68284528, CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusion

    Janssen-Cilag International N.V.

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , GEMCITABINE , PACLITAXEL , FAMOTIDINE , MK-2870, PARACETAMOL , CISPLATIN , PEMETREXED , -, -

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  7. LENALIDOMIDE, LENALIDOMIDE, DEXAMETHASONE, LENALIDOMIDE, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Newly diagnosed patients with multiple myeloma

    phase 2 small molecule active

    1 trial

  8. LOMUSTINE , Odomzo 200 mg hard capsules, VINCRISTINE, CISPLATIN

    Ningbo Cancer Hospital

    Newly Diagnosed Medulloblastoma

    phase 2 small molecule active

    1 trial

  9. LTI-03, The placebo is InhaLac® 500 (micronized lactose monohyrdate).

    Shanghai Reinovax Biologics Co.,LTD

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  10. Levothyroxine sodium new formulation

    Takeda

    Hypothyroidism

    phase 2 small molecule completed

    1 trial

  11. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  12. Lucinactant 175 mg/kg

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome, Newborn

    phase 2 small molecule terminated

    1 trial

  13. Lucinactant for Inhalation

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome, Newborn

    phase 2 other terminated

    1 trial

  14. Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion, TEMOZOLOMIDE , LOMUSTINE

    Pari Pharma GmbH

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    phase 2 small molecule active

    1 trial

  15. PREDNISONE, PREDNISOLONE, BOSENTAN

    Pari Pharma GmbH

    Newly diagnosed or relapsing Giant-cell arteritis

    phase 2 small molecule active

    1 trial

  16. Perjeta 420 mg concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    The George Institute

    Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  17. Quizartinib

    AXIM BIOTECHNOLOGIES, INC.

    newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML

    phase 2 small molecule active

    1 trial

  18. Revlimid 25 mg hard capsules, Isatuximab, Dexamethasone Tablets 2 mg, Revlimid 15 mg hard capsules, Isatuximab, VELCADE 1 mg powder for solution for injection, Revlimid 10 mg hard capsules

    Ningbo Cancer Hospital

    Newly diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  19. Xospata 40 mg film-coated tablets

    Fondazione Telethon ETS

    newly diagnosed non-M3 FLT3-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  20. idecabtagene vicleucel

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

    phase 2 small molecule active

    1 trial

  21. rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada

    Dompe' Farmaceutici S.p.A.

    Dry Eye

    phase 2 small molecule active

    1 trial

  22. the standard "3+7" regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Newly Diagnosed Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  23. A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  24. A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability and Pharmacological Effects of PT00114 in Healthy Volunteers

    Protagenic Therapeutics, Inc.new

    Phase I study in healthy male and female volunteers. Intended indication: mood disorders

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources